Valuation: CARsgen Therapeutics Holdings Limited

Market Cap 5.38B 6.33B 808M 723M 667M 605M 1.13B 76.78B 1.14B 7.98B 3.18B 40.22B 3.03B 2.96B 127B P/E 2026 *
-36.8x
P/E 2027 * -103x
Enterprise Value 4.43B 5.21B 666M 596M 550M 499M 930M 63.29B 942M 6.58B 2.62B 33.15B 2.49B 2.44B 105B EV / Sales 2026 *
15x
EV / Sales 2027 * 6.81x
Free-Float
62.5%
Yield 2026 *
-
Yield 2027 * -
10-25 CARsgen Therapeutics Holdings Limited Presents Preliminary Positive Research Results Of Satri-Cel For Adjuvant Treatment For Locally Advanced Gastric Or Gastroesophageal Junction Cancer At ESMO Congress 2026 CI
10-12 CARsgen Doses First Patient in China Trial of T-Cell Therapy for Multiple Myeloma MT
10-12 Carsgen Therapeutics Holdings Limited Completes First Patient Dose of Ct0596 in China Phase I Registrational Trial CI
09-30 Carsgen Therapeutics Holdings Limited Announces Resignation of Huaqing Guo as Non-Executive Director and Member of the Audit Committee, Effective September 30, 2026 CI
09-28 CARsgen Therapeutics Doses First Patient in CT1190B Lymphoma Trial MT
09-28 Carsgen Therapeutics Holdings Limited Completes First Patient Dose of Ct1190b in China Phase I Registrational Trial CI
09-14 Tranche Update on CARsgen Therapeutics Holdings Limited's Equity Buyback Plan announced on October 21, 2025. CI
08-18 CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-13 Certain Ordinary Shares of CARsgen Therapeutics Holdings Limited are subject to a Lock-Up Agreement Ending on 14-AUG-2026. CI
08-07 CARsgen Therapeutics Wins China IND Clearance for Lymphoma Cell Therapy MT
08-04 CARsgen Therapeutics Receives China IND Clearance for Multiple Myeloma Therapy; Shares Up 3% MT
08-03 CARsgen Therapeutics Holdings Limited Announces CT0596 Receives IND Clearance from NMPA for Treatment of Relapsed/Refractory Multiple Myeloma CI
07-14 CARsgen Therapeutics Holdings Limited Research Results On Satri-Cel Accepted For Poster Presentation At ESMO Congress 2026 CI
1 week-6.72%
Current month-10.71%
1 month-12.72%
3 months-20.61%
6 months-53.47%
Current year-24.24%
1 week 10.47
Extreme 10.47
11.93
1 month 10.47
Extreme 10.47
13
Current year 10.47
Extreme 10.47
28.6
1 year 10.47
Extreme 10.47
28.6
3 years 2.48
Extreme 2.48
28.6
5 years 2.48
Extreme 2.48
49.7
10 years 2.48
Extreme 2.48
57.25
Manager TitleAgeSince
Chief Operating Officer 49 2021-01-31
Chief Executive Officer 52 2021-01-31
Director of Finance/CFO 54 2021-02-28
Director TitleAgeSince
Chairman 52 2021-02-22
Director/Board Member 49 2018-09-12
Director/Board Member 40 2020-09-17
Date Insider Type Main position Quantity % Market Cap. Importance
7/30/26 Other

Chief Executive Officer

-7,228,000 1.2017%
7/30/26 Other

Chief Executive Officer

-7,228,000 1.2017%
7/30/26 Other

Chief Executive Officer

-7,228,000 1.2017%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.72%-32.96%+12.50% 806M
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.10%-1.05%+43.65%+147.79% 38.12B
Weighted average by Cap. +3.23%-0.30%+47.39%+161.15%

Financials

2026 *2027 *
Net sales 296M 349M 44.51M 39.83M 36.78M 33.33M 62.16M 4.23B 63M 440M 175M 2.22B 167M 163M 7.01B 659M 776M 99.02M 88.61M 81.81M 74.15M 138M 9.41B 140M 979M 390M 4.93B 371M 363M 15.6B
Net income -149M -175M -22.38M -20.03M -18.49M -16.76M -31.25M -2.13B -31.68M -221M -88.08M -1.11B -83.82M -82.06M -3.53B -55.4M -65.2M -8.32M -7.45M -6.88M -6.23M -11.63M -791M -11.78M -82.27M -32.76M -414M -31.18M -30.52M -1.31B
Net Debt -945M -1.11B -142M -127M -117M -106M -198M -13.5B -201M -1.4B -559M -7.07B -532M -521M -22.37B -889M -1.05B -134M -120M -110M -100M -187M -12.7B -189M -1.32B -526M -6.65B -501M -490M -21.06B
Projected Income Statement - Annual - CARsgen Therapeutics Holdings Limited
Logo CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.
Employees
424
Date Price Change Volume
26-10-28 HK$11.25 0.00% 861,343
26-10-27 HK$11.25 +0.72% 1,473,500
26-10-26 HK$11.17 -0.36% 765,500
26-10-23 HK$11.21 +3.60% 1,420,500
26-10-22 HK$10.82 -9.83% 2,003,500
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - CARsgen Therapeutics Holdings Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
9.561CNY
Average target price
15.74CNY
Spread / Average Target
+64.59%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CARsgen Therapeutics Holdings Limited
  1. Stock Market
  2. Stocks
  3. 2171 Stock